Author page: Ella Ye

FOR IMMEDIATE RELEASE: September 23, 2019 CONTACTS: Asian Fund for Cancer Research Bradley Gillenwater, Senior Director for Global Programs & Communications E-mail: bgillenwater@afcr.org Hugill & Ip Solicitors Marco Raccuia, Operations & Marketing Specialist E-mail: marco.raccuia@hugillandip.com              Inaugural BRACE Award Competition winner F. Joel Leong, flanked by…

Given recent innovation in cancer research and public awareness, most cancers are declining in frequency. Unfortunately, thyroid cancer is not following this trend. Thyroid cancer has actually seen an increase in frequency of about 4% every year throughout the last 10 years.…

Creator and chair of the Hong Kong Hereditary Breast Cancer Family Registry. Women’s Surgical Chapter founder with the College of Surgeons of Hong Kong—and its first chair. First woman to attain a clinical associate professorship in surgery in Hong Kong. Chief of…

The Asian Fund for Cancer Research was well-represented at the 24th Chinese Biopharmaceutical Association (CBA) Annual Conference, held 10 and 11 June 2019, in Guangzhou. The event, conducted in conjunction with the 12th China Bioindustry Convention, included some of the most highly…

Did you know that you can donate to the Asian Fund for Cancer Research in honor or in memory of someone in your life who has been impacted by cancer? Whether honoring a cancer survivor or memorializing the life of a family…

The Asian Fund for Cancer Research made this statement following the Friday, 26 July, announcement and dissemination of the Hong Kong Cancer Strategy: The Asian Fund for Cancer Research proudly supports and is committed to helping vigorously pursue the newly unveiled Hong Kong…

Cancer is anything but a straightforward disease; one tumor type can be entirely different from another not only in location, but causal agent and origin. There is differentiation even within the same type of cancer. Take sarcoma, which is in fact an umbrella term…

The Global Coalition for Adaptive Research (GCAR) announced today that the GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) clinical trial is opening its first clinical site, the Henry Ford Cancer Institute, and will begin enrolling patients this week. GBM AGILE is…